TOMSK, Jan 15 –
RIA Tomsk. The world's first safe analgesic – thiowurtzine,
obtained by changing the CL-20 explosive molecule, developed by a consortium of
Tomsk scientists with the participation of chemists of Tomsk State University
(TSU) and industrial partners, passed preclinical tests that confirmed its
medicinal properties, the press service of TSU said on Wednesday.
Earlier it was
reported that Tomsk and Biysk scientists are developing painkillers based on
hexaazoisowurtzitane (СL-20) – a substance that is a component of rocket fuel
and explosives.
According to the
TSU press service, the development of analgesics is carried out within the
framework of the federal target program "Pharma 2020" by a scientific
group, which includes specialists of the Institute for Problems of Chemical and
Energetic Technologies of the Siberian Branch of the RAS (IPCET SB RAS), TSU
and Goldberg Research Institute of Pharmacology and Regenerative Medicine
Clinic of Tomsk National Research Medical Center (Tomsk NRMC). The industrial
partners of the project – are enterprises from the innovative zone of TSU – Sibtermokhim
and SPC Chemical Technologies.
"The
world's first analgesic based on the first-in-class molecule, low-toxic and
without side effects, has successfully passed the preclinical test phase ...
The basis for the analgesic, which has no analogues, was the modified powerful
explosive molecule CL-20. Preclinical studies have confirmed its unique
medicinal properties", – is said in the report.
The new pain
relieving medication is called "thiowurtzine". The molecule of its
active substance (first-in-class) is obtained by the method of directed synthesis
from the CL-20 molecule. Three-year preclinical studies of thiowurtzine were
performed in mice, rats, rabbits, guinea pigs and drosophilae. The results
showed that in terms of strength and duration of exposure, it surpasses many
known analgesics, notes the report.
© предоставлено пресс-службой ТГУ
"The data
suggests .. that thiowurtzine does not cause effects characteristic of opioid
analgesics – there is no negative effect on the gastrointestinal tract, central
nervous system (does not cause the development of euphoria and sedation), it
does not inhibit the respiratory center and hematopoietic system. Even after
prolonged use, the analgesic does not occur drug dependence and withdrawal
syndrome", – an employee of Research Institute of Pharmacology and
Regenerative Medicine Clinic Svetlana Krylova is quoted.
Now developers
have to go through the last and most expensive stage – clinical trials of the
drug. The cost of research, giving an objective picture, starts from 0.5
billion rubles. Currently, the creators of thiowurtzine are negotiating with
several pharmaceutical companies, including abroad, and are looking for an
investor who is ready to finance clinical trials, the message emphasizes.